03.02.15
Jeff Jonker has been named president of NGM Biopharmaceuticals, Inc., and David Woodhouse, Ph.D., has been appointed chief financial officer, effective immediately.
Prior to joining the company, Mr. Jonker was senior vice president, corporate and business development at Theravance Biopharma and
Theravance, Inc. He previously served as chief business officer of Satori Pharmaceuticals and vice president of business development
and corporate strategy for Gloucester Pharmaceuticals, prior to its acquisition by Celgene. He also held leadership positions in the business development and legal groups at Genentech.
Dr. Woodhouse joins the company from Goldman Sachs, where he was managing director and co-head of U.S. Biotechnology Investment Banking. He was a member of Goldman's healthcare investment banking group for 13 years in the New York and San Francisco offices, where his responsibilities included corporate finance and mergers and acquisitions (M&A) for the biotechnology, specialty pharma and diagnostics industries. Prior to Goldman, he worked in business development and research roles at Dynavax Technologies Corp. and Amgen, Inc.
"The expansion of our management team reflects our accelerated pace of growth across the organization," said William J. Rieflin, chief
executive officer of NGM. "Jeff has been part of the team since November, and his strategic business guidance has already proven to be invaluable in consummating our recently announced collaboration with Merck. David's financial expertise and broad perspective will be vital to the company as we continue to maximize stockholder value. I'm pleased to welcome Jeff and David to NGM, and I look forward to further building out the NGM team as we significantly expand our R&D organization to deliver on our collaboration with Merck."
Prior to joining the company, Mr. Jonker was senior vice president, corporate and business development at Theravance Biopharma and
Theravance, Inc. He previously served as chief business officer of Satori Pharmaceuticals and vice president of business development
and corporate strategy for Gloucester Pharmaceuticals, prior to its acquisition by Celgene. He also held leadership positions in the business development and legal groups at Genentech.
Dr. Woodhouse joins the company from Goldman Sachs, where he was managing director and co-head of U.S. Biotechnology Investment Banking. He was a member of Goldman's healthcare investment banking group for 13 years in the New York and San Francisco offices, where his responsibilities included corporate finance and mergers and acquisitions (M&A) for the biotechnology, specialty pharma and diagnostics industries. Prior to Goldman, he worked in business development and research roles at Dynavax Technologies Corp. and Amgen, Inc.
"The expansion of our management team reflects our accelerated pace of growth across the organization," said William J. Rieflin, chief
executive officer of NGM. "Jeff has been part of the team since November, and his strategic business guidance has already proven to be invaluable in consummating our recently announced collaboration with Merck. David's financial expertise and broad perspective will be vital to the company as we continue to maximize stockholder value. I'm pleased to welcome Jeff and David to NGM, and I look forward to further building out the NGM team as we significantly expand our R&D organization to deliver on our collaboration with Merck."